SEC I	Form 4
-------	--------

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

-	-							
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

ger subject to	31
orm 5	
e. See	
ļ	orm 5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

_								
1. Name and Address of Reporting Person* Khattar Jack A. (Last) (First) (Middle)		erson*	2. Issuer Name and Ticker or Trading Symbol <u>SUPERNUS PHARMACEUTICALS INC</u> [5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
		(Middle)	SUPN]	x	Officer (give title below)	Other (specify below)		
C/O SUPERNUS PHARMACEUTICALS, INC. 1550 EAST GUDE DRIVE			3. Date of Earliest Transaction (Month/Day/Year) 02/22/2019	President, CEO				
1550 EAST GU	DE DRIVE		4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv	vidual or Joint/Group Filin	g (Check Applicable		
(Street)				Line)				
ROCKVILLE	MD	20850			Form filed by One Rep	Ū.		
(City)	(State)	(Zip)			Form filed by More tha Person	n One Reporting		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code V Amount (A) or (D) Price Reported Transaction(s) (Instr. 3 and 4)			(1150.4)				
Common Stock								453,065	D	
Common Stock								2,900 ⁽¹⁾	Ι	By son
Common Stock								1,085,950	I	By the KBT Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Employee Stock Option (Right to Buy)	\$36.75	02/22/2019		A		300,000		(2)	02/22/2029	Common Stock	300,000	\$0	300,000	D	

Explanation of Responses:

1. The Reporting Person disclaims beneficial ownership of the shares held by his son, who shares the Reporting Person's household, and this report should not be deemed an admission that the Reporting Person is the beneficial owner of his son's shares for purposes of Section 16 or for any other purpose.

2. The option vests in four equal annual installments beginning on February 22, 2020.

/s/ Gregory S. Patrick, as

attorney-in-fact

02/26/2019

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 \ast If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.